drugset
drugset / Trial / NCT05288881

Single Ascending Dose Study of ANX105

NCT05288881 ↗

Phase 1 Completed 23 enrolled Annexon, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ANX105 administered intravenously (IV) to healthy participants.

Timeline

Start
2022-02-28
Primary completion
2023-06-19
Completion
2023-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject ANX105 Unknown — Intravenous

Indications

No indication recorded.